Polycythemia Vera - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 64 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Polycythemia Vera - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Polycythemia Vera - Pipeline Review, H2 2014', provides an overview of the Polycythemia Vera's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Polycythemia Vera and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Polycythemia Vera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Polycythemia Vera pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Polycythemia Vera
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Polycythemia Vera pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Polycythemia Vera Overview 6
Therapeutics Development 7
Pipeline Products for Polycythemia Vera - Overview 7
Pipeline Products for Polycythemia Vera - Comparative Analysis 8
Polycythemia Vera - Therapeutics under Development by Companies 9
Polycythemia Vera - Therapeutics under Investigation by Universities/Institutes 10
Polycythemia Vera - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Polycythemia Vera - Products under Development by Companies 14
Polycythemia Vera - Products under Investigation by Universities/Institutes 15
Polycythemia Vera - Companies Involved in Therapeutics Development 16
Bristol-Myers Squibb Company 16
Italfarmaco S.p.A. 17
Onconova Therapeutics, Inc. 18
PharmaEssentia Corporation 19
miRagen Therapeutics, Inc. 20
Polycythemia Vera - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 25
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
dasatinib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
peginterferon alfa-2b - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
givinostat - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
rigosertib sodium - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
MGN-4893 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecules to Inhibit JAK for Oncology and Hematological Disorders - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Polycythemia Vera - Recent Pipeline Updates 45
Polycythemia Vera - Dormant Projects 50
Polycythemia Vera - Discontinued Products 51
Polycythemia Vera - Product Development Milestones 52
Featured News & Press Releases 52
Aug 05, 2014: FDA Accepts Supplemental New Drug Application for Jakafi (ruxolitinib) and Priority Review Granted 52
Jul 23, 2014: Incyte Announces Top-Line Results from RELIEF Trial of Ruxolitinib in Patients with Polycythemia Vera 52
Jun 03, 2014: Pivotal Phase III Data in Polycythemia Vera Show that Jakafi (ruxolitinib) Achieved Superior Disease Control Compared to Best Available Therapies 54
Mar 07, 2014: Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera 55
Mar 07, 2014: Novartis announces positive Phase III study for Jakavi in patients with rare blood cancer polycythemia vera 55
Oct 10, 2013: AOP Orphan Pharmaceuticals Announces Progress of Pivotal Phase III Trial PROUD-PV of Novel Mono-Pegylated Interferon Alpha 2b for the Treatment of Polycythemia Vera 57
Feb 13, 2013: Novartis's Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance 57
Dec 10, 2012: AOP Orphan Pharma Reports Positive Phase II Data Of New Mono-pegylated Interferon Alpha 2b For Treatment Of Polycythemia Vera 59
Dec 08, 2010: Incyte Provides Positive Phase II Trial Results Of INCB18424 In Myeloproliferative Neoplasms 59
Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting 61
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 64
Disclaimer 64

List of Tables
Number of Products under Development for Polycythemia Vera, H2 2014 7
Number of Products under Development for Polycythemia Vera - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Polycythemia Vera - Pipeline by Bristol-Myers Squibb Company, H2 2014 16
Polycythemia Vera - Pipeline by Italfarmaco S.p.A., H2 2014 17
Polycythemia Vera - Pipeline by Onconova Therapeutics, Inc., H2 2014 18
Polycythemia Vera - Pipeline by PharmaEssentia Corporation, H2 2014 19
Polycythemia Vera - Pipeline by miRagen Therapeutics, Inc., H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Polycythemia Vera Therapeutics - Recent Pipeline Updates, H2 2014 45
Polycythemia Vera - Dormant Projects, H2 2014 50
Polycythemia Vera - Discontinued Products, H2 2014 51